Baidu
map

PLoS One:缺血性卒中后要早点坐起来?

2016-04-10 MedSci MedSci原创

背景:长时间制动与住院期间并发症的发生相关。然而,没有明确的指南推荐缺血性中风患者早期运动是可行的。目的:由于已证明早期运动是可行的和安全的,研究者假设,早期坐起来可能对卒中患者的预后是有益的。方法:这项多中心前瞻性研究以随机对照的方式,检测缺血性卒中急性期患者两种不同坐的方式。纳入标准为,患者年龄18岁以上,无大面积脑梗死或任何坐的禁忌症。在早期坐起来组,患者尽可能早的离开床坐起来,但是不能迟于

背景:长时间制动与住院期间并发症的发生相关。然而,没有明确的指南推荐缺血性中风患者早期运动是可行的。

目的:由于已证明早期运动是可行的和安全的,研究者假设,早期坐起来可能对卒中患者的预后是有益的。

方法:这项多中心前瞻性研究以随机对照的方式,检测缺血性卒中急性期患者两种不同坐的方式。纳入标准为,患者年龄18岁以上,无大面积脑梗死或任何坐的禁忌症。在早期坐起来组,患者尽可能早的离开床坐起来,但是不能迟于卒中后1天;然而,延迟离开床坐起来组,首次坐起来在卒中后3天。主要预后为卒中后3个月mRS(0-2)。次要预后为:a)医疗并发症,b)住院天数和c)对手术的耐受性。

结果:研究共有167名患者,随机化后排除29例。138例患者中,63例在早期坐起来组,75例在延迟坐起来组。两组间,卒中患者的主要预后没有差异,3个月mRS评分为0-2的比率分别为76.2%,77.3%。两组间次要预后也无明显差异,并且在实验过程中,两组耐受性良好。

结论:由于入组患者较慢,分析的数据比预期的少。结果是,研究者只能检测到早期坐起来的有益的/有害的影响为+ / - 15%,并且效力为37%。然而,研究数据足以排除高于25%的效应值,效力为80%,显示早期坐起来不可能对卒中预后有直接的影响。另外,研究者不能对主要预后进行双盲评估。考虑到这些不足,研究结果可能有助于指导指定更有效地卒中康复措施,并且指导设计未来的急性卒中试验,涉及床上的活动或者,其他运动方案。

原文出处:

Herisson F, Godard S, Early Sitting in Ischemic Stroke Patients (SEVEL): A Randomized Controlled Trial. PLoS One. 2016 Mar 29

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1806074, encodeId=ef7e18060e45a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 23 22:48:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671239, encodeId=37b816e12392c, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Jan 06 17:48:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892738, encodeId=81691892e3840, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Sep 17 15:48:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789793, encodeId=3da61e8979377, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Nov 27 05:48:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78085, encodeId=b70fe80855d, content=文章值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78086, encodeId=7a18e8086a9, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1806074, encodeId=ef7e18060e45a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 23 22:48:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671239, encodeId=37b816e12392c, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Jan 06 17:48:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892738, encodeId=81691892e3840, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Sep 17 15:48:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789793, encodeId=3da61e8979377, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Nov 27 05:48:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78085, encodeId=b70fe80855d, content=文章值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78086, encodeId=7a18e8086a9, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1806074, encodeId=ef7e18060e45a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 23 22:48:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671239, encodeId=37b816e12392c, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Jan 06 17:48:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892738, encodeId=81691892e3840, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Sep 17 15:48:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789793, encodeId=3da61e8979377, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Nov 27 05:48:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78085, encodeId=b70fe80855d, content=文章值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78086, encodeId=7a18e8086a9, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1806074, encodeId=ef7e18060e45a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 23 22:48:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671239, encodeId=37b816e12392c, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Jan 06 17:48:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892738, encodeId=81691892e3840, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Sep 17 15:48:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789793, encodeId=3da61e8979377, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Nov 27 05:48:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78085, encodeId=b70fe80855d, content=文章值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78086, encodeId=7a18e8086a9, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1806074, encodeId=ef7e18060e45a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 23 22:48:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671239, encodeId=37b816e12392c, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Jan 06 17:48:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892738, encodeId=81691892e3840, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Sep 17 15:48:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789793, encodeId=3da61e8979377, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Nov 27 05:48:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78085, encodeId=b70fe80855d, content=文章值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78086, encodeId=7a18e8086a9, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2016-04-14 李继凯

    文章值得学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1806074, encodeId=ef7e18060e45a, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Sep 23 22:48:00 CST 2016, time=2016-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671239, encodeId=37b816e12392c, content=<a href='/topic/show?id=9f4e360191a' target=_blank style='color:#2F92EE;'>#卒中后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36019, encryptionId=9f4e360191a, topicName=卒中后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff7426824786, createdName=waiwai3039, createdTime=Fri Jan 06 17:48:00 CST 2017, time=2017-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892738, encodeId=81691892e3840, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Sep 17 15:48:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789793, encodeId=3da61e8979377, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Sun Nov 27 05:48:00 CST 2016, time=2016-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78085, encodeId=b70fe80855d, content=文章值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78086, encodeId=7a18e8086a9, content=不错不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:28:00 CST 2016, time=2016-04-14, status=1, ipAttribution=)]
    2016-04-14 李继凯

    不错不错

    0

相关资讯

PLoS One:缺血性卒中患者,右颈动脉狭窄和认知功能相关

探讨急性缺血性脑卒中患者颈动脉狭窄与认知功能障碍的关系,并提供重要的临床意义。研究者测量了3116名急性缺血性脑卒中患者,颈动脉狭窄程度并记录简易精神状态检查评分(MMSE)。应用多变量回归分析,颈动脉狭窄与认知功能障碍(MMSE评估)的关联。也对其他感兴趣的临床变量进行了研究。在校正了年龄、性别、教育程度、婚姻、饮酒、吸烟、体力活动、高血压、糖尿病、高胆固醇血症、心房纤颤、心肌梗死、NIHSS(

PLoS One:涉及岛叶皮质的缺血性卒中,可能是心源性栓塞的危险因素

目的:评估心源性脑栓塞是否与岛叶部位缺血性脑卒中相关。方法:识别症状开始7天内的住院的缺血性卒中患者。基于弥散加权成像,研究包括大脑中动脉(MCA)中缺血性病变。根据梗死是否涉及岛叶,将患者分为两组中一组。主要预后为根据是否涉及岛叶,比较心源性脑栓塞的频率。共有MCAO供血区发生缺血性卒中的患者,112名(8.5%)涉及到岛叶。与未涉及岛叶(30.4%)的患者相比,涉及岛叶卒中(52.7%)的患者

Stroke:急性使用可卡因增加了早发性缺血性脑卒中的风险

虽然病例报告早就确定了使用可卡因和缺血性脑卒中(IS)之间的关联,但很少有流行病学研究阐述青壮年IS与使用可卡因的关联,通过定期的,途径和使用频率进行确定。研究人员进行了一项基于人群的病例对照研究,通过1090例患者和1154名对照来调查使用可卡因和青年人IS发病的关联。卒中病例均在15至49岁之间。采用Logistic回归分析,以评估使用可卡因和IS之间的关联,其中的IS是经过了有或没有潜在的混

PLoS One:A2DS2分数可预测中国缺血性卒中患者卒中相关肺炎和住院死亡

背景和目的:卒中相关性肺炎(SAP)是常见的并发症,并且也是住院期间死亡的重要原因之一。A2DS2(年龄、心房纤颤、吞咽困难、性别、卒中的严重程度)评分是柏林卒中注册开发,能够很好的预测SAP的发生。研究者旨在识别A2DS2评分和SAP之间的关联,并且确定A2DS2评分是否能预测中国人群急性缺血性卒中的死亡。方法:研究者进行了一项回顾性的研究。将1239名急性缺血性脑卒中患者分为低A2DS2组(0

NEJM:吡格列酮治疗缺血性卒中或短暂性脑缺血发作效果一般

尽管使用当前的预防性疗法,缺血性中风或短暂性脑缺血发作(TIA)患者的未来心血管事件的风险增加。胰岛素抗性的识别作为中风和心肌梗塞的危险因素,提高了吡格列酮治疗的可能性,改善了胰岛素的敏感性,可能增加脑血管疾病的患者受益的可能性。在这个多中心,双盲试验中,研究人员随机分配3876例近期患缺血性卒中或TIA的患者分别接受吡格列酮(目标剂量,每天45毫克)或安慰剂。符合条件的患者没有糖尿病,但被发现在

Stroke:DASH饮食可降低缺血性卒中风险

坚持饮食疗法停止高血压(DASH)饮食可降低高血压的风险,高血压是脑卒中的主要危险因素。研究人员探讨了是否坚持DASH饮食可降低卒中的发病率。研究人群包括74404名男性和女性(45-83岁),基线时无卒中,这些参与者来自瑞典男性的队列和瑞典乳房X光摄影队列。饮食通过饮食频率问卷评估。一种改进的DASH饮食评分是基于对蔬菜,水果,豆类和坚果,全谷类,低脂奶制品,红肉和加工肉类和含糖饮料消费的产生的

Baidu
map
Baidu
map
Baidu
map